沙利度胺治疗特发性骨髓纤维化的研究进展  

Advances in Thalidomide Therapy for Idiopathic Myelofibrosis

作　　者：宋丽[1] 陈嘉林[1] 

机构地区：[1]中国医学科学院北京协和医学院北京协和医院普通内科,北京100730

出　　处：《中国医学科学院学报》2009年第5期651-653,共3页Acta Academiae Medicinae Sinicae

摘　　要：特发性骨髓纤维化是慢性骨髓增殖性疾病的一种,预后较差。造血干细胞移植能改善该病预后,但只适用于少数患者。目前多采用姑息性治疗措施,如雄激素、羟基脲等,疗效并不满意。沙利度胺兼具抗血管新生和抑制细胞因子的特性,在特发性骨髓纤维化的治疗中有一定疗效。Idiopathic myelofibros is a Philadelphia-negative chronic myeloproliferative disorder. Potentially curative therapies, such as stem-cell transplantation, are reserved only for a minority of patients. Currently palliative therapies such as androgen and hydroxycarbamide are commonly used but with poor results. Thalidomide has anti-angiogenic effect and also can inhibit cytokines, and therefore plays a certain role in the treatment of a subset of idiopathic myelofibros.

关 键 词：特发性骨髓纤维化 沙利度胺 治疗 

分 类 号：R551.3[医药卫生—血液循环系统疾病]